Updated:
Inhibitor Therapeutics
Inhibitor Therapeutics, Inc. trades publicly under the ticker OTCQB:INTI. The company develops and commercializes therapies for patients with cancer and...
Overview
Inhibitor Therapeutics, Inc. trades publicly under the ticker OTCQB:INTI. The company develops and commercializes therapies for patients with cancer and non-cancerous proliferation disorders.
General information
Sector focus
Frequently asked questions
What is Inhibitor Therapeutics' lead drug program?
The company's primary program involves repurposing bortezomib, a proteasome inhibitor, for relapsed or refractory multiple myeloma. It has not reported Phase III trial data or regulatory submissions.
Who manages investment decisions at Inhibitor Therapeutics?
The company has not identified a CEO, CIO, or investment team in public filings. Its executive management and board composition are not disclosed in a way that clarifies investment authority.
Does Inhibitor Therapeutics have any institutional investors?
The firm has not publicly named any institutional or accredited investors. Its stock trades on the OTC market, which does not require disclosure of major holders.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: